Compare Adaptive Biotechnologies Corp (ADPT) vs EOG Resources Inc (EOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs EOG Resources Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.99 (market cap $3.33B), while EOG Resources Inc trades at $136.77 (market cap $71.66B). The key difference: EOG Resources Inc is far larger — about 21.5× Adaptive Biotechnologies Corp's market cap, and EOG Resources Inc pays a 3.03% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EOG | |
|---|---|---|
Market Cap | $3.33B | $71.66B |
Sector | Health | Energy |
52-Week High | $22.37 | $149.89 |
52-Week Low | $10.24 | $101.78 |
Enterprise Value | $3.19B | $76.12B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EOG Resources trades at $134.54, up 2.88% today, with a bearish technical signal but strong fundamentals including a P/E of 12.72 and net income margin of 23.39%. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected August 5, 2026. Recent news highlights strong free cash flow potential and shareholder returns, while analyst consensus is a Buy with a $157 price target.
The outlook for EOG is positive due to robust profitability, consistent earnings beats, and favorable oil price trends. Key risks include volatile energy markets and high capital expenditures. With no sell ratings from analysts and a price target implying 17% upside, the stock presents a compelling opportunity for value-oriented investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
